FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Vashington, | D.C. | 20549 | |
|-------------|------|-------|--|
|-------------|------|-------|--|

| Washi | ngton, D.C. 20549 | |
|---------------------|-------------------|------------------|
| | | |
| STATEMENT OF CHANGI | ES IN BENEFICIAL | OWNERSHIP |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| Name and Address of Reporting Person* Cummings Keith Lamont | | | | | 2. Issuer Name and Ticker or Trading Symbol PLIANT THERAPEUTICS, INC. [PLRX] | | | | | | | (Che | ck all appli Directo | cable) | g Per | son(s) to Iss 10% Ov Other (s | vner | | |
|---|--|--|---|-----------------|---|---|----------|---|--|---------|--|---|--|---|---|-------------------------------------|--|---------------------------------------|--|
| (Last) | , | irst) | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023 | | | | |) | below) | | ncial | below) | вреспу | | | |
| 260 LITTLEFIELD AVENUE | | | | 4. If <i>i</i> | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | Line | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | | | |
| (Street) SOUTH FRANCI | () | A | 94080 | | | | | | | | | | | | | iled by Mor | | n One Repo | |
| (City) | (S | tate) | (Zip) | | $ _{\Box}$ | Rule 10b5-1(c) Transaction Indication | | | | | | | ontract, instruction or written plan that is intended to | | | | | | |
| | | | | | | satis | fy the a | affirmative | defense o | onditio | ns of Rule : | 10b5-1(c). | See II | nstructio | n 10. | | | | |
| | | Tab | le I - Noi | n-Deriv | ative/ | Se | curit | ies Ac | quired | Dis | posed c | of, or B | ene | ficiall | y Owned | 1 | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | Execution Date, | | Transaction Disposed (Code (Instr. 5) | | ties Acquired (A) or d Of (D) (Instr. 3, 4 and | | | 5. Amou Securition Benefici Owned I Reporte | es Formally (D) (Following (I) (I | | n: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | | | | | Code | v | Amount | (A) or (D) Pi | | Price | Transac (Instr. 3 | tion(s) | | | (111511.4) | |
| Common Stock 06/13. | | | /2023 | | M | | 30,75 | 30,750 A \$ | | \$2.08 | 8 185,020 | | | D | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| Derivative Conversion Date | | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | 4. Transaction Code (Instr. 8) | | n of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | curity | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(: (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisa | | xpiration ate | Title | or Nu of | ımber | | | | | |
| Stock Option (Right to Buy) | \$2.08 | 06/13/2023 | | | М | | | 30,750 | (1) | O | 1/24/2029 | Common Stock | 30 |),750 | \$0.00 | 97,047 | , | D | |

Explanation of Responses:

1. 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vested in substantially equal monthly installments thereafter, all of which were subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

/s/ Mike Ouimette, attorney-in-06/14/2023

fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.